Not known Facts About Imipenem
The first finish point was the protection and tolerability of sifalimumab. Remedy-emergent adverse events (AEs) and critical AEs (SAEs) and their severity, end result, and any partnership into the review medication had been recorded via the investigator all over the study. AEs ended up regarded as more likely to be connected to research medication